Metabolon Collaborates with The Michael J. Fox Foundation to Advance Multiomic Analyses for Parkinson's Research
Partnership supports expanded biomarker discovery efforts within MJFF's Parkinson's Progression Markers Initiative MORRISVILLE, N.C., March 17, 2026 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a...
XellSmart Secures FDA Clearance for Three Phase I INDs of Allogeneic iPSC-Derived Cell Therapies Targeting Major CNS Diseases: Parkinson's Diseases, Spinal Cord Injury and ALS
SUZHOU, China, June 3, 2025 /PRNewswire/ -- XellSmart Biomedical Co., Ltd. (Suzhou/Shanghai, China) is a leading biotechnology company dedicated to the development of innovative iPSC-derived cell therapies. To date, the company has received seven...